HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CARB update

This article was originally published in The Rose Sheet

Executive Summary

California Air Resources Board does not support postponing current plans for collecting consumer product fees since any delay would require manufacturers to pay fees for two fiscal years at about the same time, CARB staff states during Consumer Products Fee Regulation Workgroup teleconference June 19. At the session, CARB staff responded to comments it received following a call for public input on new fees on certain volatile organic-compound-containing consumer products. The Cosmetic, Toiletry and Fragrance Association has urged CARB slow down the regulatory timetable (1"The Rose Sheet" June 2, 2003, p. 5). Workgroup also discussed its staff report and proposed fee regulation, which was released June 6. Second CARB public workshop will be June 24...

You may also be interested in...



CARB Consumer Product Fee Apportionment Details Requested By CTFA

The California Air Resources Board should provide "detailed" information to consumer product manufacturers on the planned apportionment of fees across the industry and the allocation of funds collected to finance activities regulating consumer products, the Cosmetic, Toiletry and Fragrance Association asserts in recent comments

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel